-
N-MYC/eIF4G1 Axis in inv(16) AML: Mechanisms and Research To
2026-06-17
Peramangalam et al. uncover that N-MYC, regulated by a novel enhancer, sustains inv(16) acute myeloid leukemia cell survival through eIF4G1, a newly identified critical target. Their work clarifies the role of the CBFβ-SMMHC fusion protein in leukemogenesis and outlines the therapeutic rationale for targeting the N-MYC/eIF4G1 axis in future acute myeloid leukemia research.
-
Streptavidin-FITC: Precision Fluorescent Detection in Biotin
2026-06-17
Streptavidin-FITC enables ultrasensitive, quantitative detection of biotinylated molecules across immunohistochemistry, flow cytometry, and advanced nanoparticle tracking. Leveraging APExBIO’s robust conjugate, researchers can streamline workflows, troubleshoot pitfalls, and achieve reproducible results in complex biological systems.
-
Clozapine in Schizophrenia Research: Protocols & Troubleshoo
2026-06-16
Clozapine stands apart as an atypical antipsychotic medication, uniquely enabling advanced schizophrenia models via multi-receptor antagonism and ERK1/2 activation. This guide details actionable workflows, practical troubleshooting, and data-driven enhancements to maximize the power of APExBIO Clozapine across in vitro and in vivo neuroscience research.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X): Technical Use
2026-06-16
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is designed to prevent protein degradation during extraction by inhibiting a broad spectrum of proteases, without interfering with assays sensitive to divalent cations. It is most appropriate for workflows such as Western blotting, Co-IP, and kinase assays, but should not be used where DMSO or the included inhibitors may impact downstream applications.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X): Practical Use
2026-06-15
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) addresses protein degradation during extraction and analysis, especially when downstream workflows require compatibility with divalent cations. It should not be used in assays where metalloprotease inhibition by EDTA is essential or where DMSO is incompatible.
-
AI-10-49: Selective CBFβ-SMMHC Inhibitor for AML Research
2026-06-15
AI-10-49 is a potent, selective inhibitor of the leukemia oncoprotein CBFβ-SMMHC, crucial for acute myeloid leukemia research. It disrupts the CBFβ-SMMHC/RUNX1 interaction, restoring normal transcriptional regulation and inducing leukemic cell apoptosis. Peer-reviewed and product data substantiate its specificity, efficacy, and in vivo translational potential.
-
Protease and Phosphatase Inhibitor Cocktail: Advanced Assay
2026-06-14
Maintain protein integrity and phosphorylation with the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O). This APExBIO solution streamlines sensitive protein extraction workflows, empowers precision in post-translational modification studies, and overcomes common pitfalls in cell signaling research.
-
Cyclosporin A (B1922): Technical Guide for Research Workflow
2026-06-13
Cyclosporin A is a well-characterized immunosuppressant and cyclophilin inhibitor, critical for dissecting T-cell signaling, apoptosis, and viral entry mechanisms in cell and animal models. This guide enables researchers to implement Cyclosporin A robustly in autoimmune disorder research, apoptosis modulation, and retinal ischemic injury protocols, while highlighting technical boundaries and best practices. Use is not recommended where water solubility or long-term solution stability is required.
-
METTL3-m6A-LEPR Axis: Placental mRNA Modification in FGR Pat
2026-06-12
This study uncovers how METTL3-catalyzed N6-methyladenosine (m6A) modification of the leptin receptor (LEPR) mRNA is diminished in placentas from fetal growth restriction (FGR) pregnancies, impairing trophoblast function. The findings clarify a key epitranscriptomic mechanism underlying FGR and highlight a promising biomarker axis for prediction and therapeutic targeting.
-
Refining In Vitro Cancer Drug Evaluation: Insights from Schw
2026-06-12
Schwartz's dissertation advances the evaluation of anti-cancer drugs by rigorously distinguishing between proliferation inhibition and cell death using in vitro assays. These methodological refinements enable more precise interpretation of drug efficacy, particularly for epigenetic modulators such as HDAC inhibitors, and have broad implications for translational cancer research.
-
MOF Nanoparticle Synergy: Photothermal and Immunotherapy in
2026-06-11
Hao et al. report a modular, glutathione-responsive MOF nanoparticle system integrating indocyanine green and a PD-1 inhibitory peptide for combined photothermal and immune-based melanoma therapy. This dual-action platform demonstrates precise tumor targeting, controlled therapeutic release, and enhanced immune activation, suggesting promise for advanced oncological interventions.
-
TP53-Dependent Antitumor Effects of DHODH Inhibition in NPC
2026-06-11
Dong et al. provide compelling evidence that targeting dihydroorotate dehydrogenase (DHODH) inhibits nasopharyngeal carcinoma (NPC) primarily through a TP53-dependent mechanism. Their work clarifies the central role of nucleic acid metabolism in NPC progression and identifies DHODH inhibition as a promising therapeutic strategy, especially in tumors with intact TP53.
-
Leupeptin Hemisulfate Salt: Precision in Protease Activity R
2026-06-10
Leupeptin hemisulfate salt delivers unmatched control in regulating serine and cysteine proteases, enabling rigorous workflows in protein degradation, viral replication studies, and autophagy research. This article unpacks optimized experimental protocols, troubleshooting strategies, and translational advances made possible by APExBIO's high-purity Leupeptin, Microbial (Leupeptin hemisulfate).
-
Imipramine in Lipid-Autophagy Crosstalk: Next-Gen Cancer Res
2026-06-10
Explore Imipramine’s unique role as a tricyclic antidepressant and modulator of lipid-driven autophagy in advanced cancer and neuroimmunology research. This article delivers a mechanistic deep dive and practical protocols, connecting lipidomics and sphingolipid metabolism for future-ready assay design.
-
Phenylmethanesulfonyl Fluoride in Serine Protease Inhibition
2026-06-09
Phenylmethanesulfonyl fluoride (PMSF) is a gold-standard irreversible serine protease inhibitor essential for preserving protein integrity during extraction and Western blotting. This guide translates the latest research and expert protocols into actionable workflows—ensuring optimal enzyme inhibition, reproducibility, and troubleshooting for advanced cell signaling and disease model applications.